BioSpace News Archive

At the 7th annual Travis Manion Foundation (TMF) Gala in Philadelphia, Wounded Warrior Project® (WWP) was honored with the 2018 Community Leadership Award.

In an effort to help address adolescent drug abuse and misuse in Pennsylvania, The Rite Aid Foundation is bringing the Prescription Drug Safety program, an innovative digital course about prescription drug abuse prevention, to Scranton-area high schools.

The Ontario Bioscience Innovation Organization (OBIO®) is announcing a national call for applications from health science companies who are seeking Series A or beyond investments to participate in the OBIO 2019 Niagara Investment Summit on February 20-22, 2019.

Through Triple Play, Boys & Girls Clubs of America and the Anthem Blue Cross and Blue Shield Foundation are delivering education and programming that promote the importance of physical activity and proper nutrition, and enable youth to build the skills needed to overcome environmental factors that can negatively impact health and wellness.

International medical imaging IT and cybersecurity company Sectra (STO: SECT B) is growing in the medical IT and cybersecurity markets through collaboration with new and existing customers.

Concord Medical Services Holdings Limited today announced that it will hold its 2018 annual general meeting of shareholders on December 29, 2018, at 10:00 a.m. (Beijing Time).

GB Sciences, Inc. (OTCQB: GBLX) announces on November 19, 2018, the Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, on behalf of the Louisiana State University Agricultural Center, entered into a Master Research and Development Agreement with GB Sciences Louisiana, LLC.

Bio-Thera Solutions, a clinical-stage pharmaceutical company, today announced that patient dosing has begun in a Phase I clinical study of BAT4306F in relapsed/refractory CD20-positive B-cell non-Hodgkin’s lymphoma patients.

HealthTrackRx®, a clinical solutions company that assists healthcare providers with monitoring patients on prescription opioids, has now enrolled more than 30,000 patients in their GuideMed® program

Eisai announced today that the first investigational drug candidate from their drug discovery collaboration with University College London (UCL) is to enter Phase I clinical trials for Alzheimer’s disease (AD) in early 2019.